{"success":true,"data":{"pressRelease":{"id":"133899","rtpr_id":"nGNX905KZd","ticker":"ARTV","exchange":"NASDAQ","all_tickers":["ARTV"],"title":"Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in September","author":"Globe Newswire","published_at":"2026-09-02T12:30:00.650Z","article_body":"SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc.\n(https://www.globenewswire.com/Tracker?data=odb1GBUYsbRDiHXf2Ej8zCd1jXGIUKmYjA5DUFWPwiOE4QzA9APif55BGkcvlgf6l-1nKu18y72Yl6FrjaFfoov2CmbWCCvS0htQvwf1t0_MUF8_nA1VnMzPzoU5FgE6)\n(Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission\nis to develop effective, safe and accessible cell therapies for patients with\ndebilitating autoimmune diseases, today announced that management will\nparticipate at the following investor conferences:\n* 2026 Cantor Global Healthcare Conference – live fireside chat on\nWednesday, September 9, 2026 at 10:20 am EDT\n\n\n* H.C. Wainwright 28th Annual Global Investment Conference – live fireside\nchat on Monday, September 14, 2026 at 2:30 pm EDT\nThe Artiva management team will also be available to participate in 1x1\nmeetings with investors who are registered to attend the conferences.\n\nTo access the audio webcast and subsequent archived recording of this and\nother company presentations, please visit the Investors\n(https://www.globenewswire.com/Tracker?data=nn6WyZPJtvssMGB6LyulYfrqF-gI9TWnl1h3YnQhfLdf2gudXt5blD_rAcjR6eKEEadTPu6_Uh6CxL6NYl5h9lv9vN8Zos6MdXgflt1_7nnwUH3mCxKYWEHizmi1U9dnofdC7GQ33YRBO8GOwZBZ2jYVG0Ul3hhScP63OOxX3l0=)\nsection of Artiva’s website. The archived audio webcast will remain\navailable for replay on Artiva’s website for 90 days.\n\nAbout Artiva Biotherapeutics\nArtiva is a clinical-stage biotechnology company whose mission is to develop\neffective, safe and accessible cell therapies for patients with debilitating\nautoimmune diseases. Artiva is initiating a Phase 3 registrational trial of\nits lead program, AlloNK(®) (also known as AB-101), in refractory rheumatoid\narthritis (RA) in the second half of 2026. Initial clinical data evaluating\nAlloNK in combination with anti-CD20 antibodies have demonstrated encouraging\nactivity across multiple B-cell-driven autoimmune diseases, together with a\ntolerability profile supportive of outpatient administration. AlloNK is an\nallogeneic, off-the-shelf, non-genetically modified, cryopreserved natural\nkiller (NK) cell therapy candidate designed to enhance the antibody-dependent\ncellular cytotoxicity of anti-CD20 antibodies and drive deep B-cell depletion.\nArtiva is developing AlloNK to drive deep B-cell depletion through a scalable,\noutpatient-administered treatment regimen compatible with community\nrheumatology settings. In addition to refractory RA, AlloNK is being evaluated\nin Sjögren disease, systemic sclerosis and myositis.\n\nArtiva is headquartered in San Diego, California. For more information, please\nvisit www.artivabio.com.\n\nForward-Looking Statements\nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995. Statements in this press\nrelease that are not statements of historical fact are forward-looking\nstatements. Such forward-looking statements include, without limitation,\nstatements regarding: expectations of Artiva regarding the potential benefits,\naccessibility, effectiveness and safety of AlloNK; Artiva's Phase 3\nregistrational trial for AlloNK(®); and Artiva's participation in the 2026\nCantor Global Healthcare Conference and H.C. Wainwright 28th Annual Global\nInvestment Conference. These forward-looking statements are based on the\nbeliefs of the management of Artiva as well as assumptions made by and\ninformation currently available to Artiva. Such statements reflect the current\nviews of Artiva with respect to future events and are subject to known and\nunknown risks and uncertainties, including, without limitation, risks inherent\nin developing product candidates and risks related to the legal and regulatory\nframework for the industry. In light of these risks and uncertainties, the\nevents or circumstances referred to in the forward-looking statements may not\noccur. These and other factors that may cause Artiva's actual results to\ndiffer from current expectations are discussed in Artiva's filings with the\nSecurities and Exchange Commission (the “SEC”), including the section\ntitled “Risk Factors” in Artiva's Quarterly Report on Form 10-Q for the\nquarter ended June 30, 2026. You are cautioned not to place undue reliance on\nthese forward-looking statements, which speak only as of the date this press\nrelease is given. Except as required by law, Artiva undertakes no obligation\nto publicly update any forward-looking statements, whether as a result of new\ninformation, future events or otherwise.\n\nContacts\n\nInvestors & Media\nNoopur Batsha Liffick, MPH\nNBL LifeSci Advisory LLC\nir@artivabio.com\n\nSource: Artiva Biotherapeutics, Inc.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/0392544b-ecff-4590-9eed-59c934e1ba4d)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX905KZd","title":"Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in September","author":"Globe Newswire","ticker":"ARTV","created":"2026-09-02T12:30:00.650Z","tickers":["ARTV"],"exchange":"NASDAQ","article_body":"SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc.\n(https://www.globenewswire.com/Tracker?data=odb1GBUYsbRDiHXf2Ej8zCd1jXGIUKmYjA5DUFWPwiOE4QzA9APif55BGkcvlgf6l-1nKu18y72Yl6FrjaFfoov2CmbWCCvS0htQvwf1t0_MUF8_nA1VnMzPzoU5FgE6)\n(Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission\nis to develop effective, safe and accessible cell therapies for patients with\ndebilitating autoimmune diseases, today announced that management will\nparticipate at the following investor conferences:\n* 2026 Cantor Global Healthcare Conference – live fireside chat on\nWednesday, September 9, 2026 at 10:20 am EDT\n\n\n* H.C. Wainwright 28th Annual Global Investment Conference – live fireside\nchat on Monday, September 14, 2026 at 2:30 pm EDT\nThe Artiva management team will also be available to participate in 1x1\nmeetings with investors who are registered to attend the conferences.\n\nTo access the audio webcast and subsequent archived recording of this and\nother company presentations, please visit the Investors\n(https://www.globenewswire.com/Tracker?data=nn6WyZPJtvssMGB6LyulYfrqF-gI9TWnl1h3YnQhfLdf2gudXt5blD_rAcjR6eKEEadTPu6_Uh6CxL6NYl5h9lv9vN8Zos6MdXgflt1_7nnwUH3mCxKYWEHizmi1U9dnofdC7GQ33YRBO8GOwZBZ2jYVG0Ul3hhScP63OOxX3l0=)\nsection of Artiva’s website. The archived audio webcast will remain\navailable for replay on Artiva’s website for 90 days.\n\nAbout Artiva Biotherapeutics\nArtiva is a clinical-stage biotechnology company whose mission is to develop\neffective, safe and accessible cell therapies for patients with debilitating\nautoimmune diseases. Artiva is initiating a Phase 3 registrational trial of\nits lead program, AlloNK(®) (also known as AB-101), in refractory rheumatoid\narthritis (RA) in the second half of 2026. Initial clinical data evaluating\nAlloNK in combination with anti-CD20 antibodies have demonstrated encouraging\nactivity across multiple B-cell-driven autoimmune diseases, together with a\ntolerability profile supportive of outpatient administration. AlloNK is an\nallogeneic, off-the-shelf, non-genetically modified, cryopreserved natural\nkiller (NK) cell therapy candidate designed to enhance the antibody-dependent\ncellular cytotoxicity of anti-CD20 antibodies and drive deep B-cell depletion.\nArtiva is developing AlloNK to drive deep B-cell depletion through a scalable,\noutpatient-administered treatment regimen compatible with community\nrheumatology settings. In addition to refractory RA, AlloNK is being evaluated\nin Sjögren disease, systemic sclerosis and myositis.\n\nArtiva is headquartered in San Diego, California. For more information, please\nvisit www.artivabio.com.\n\nForward-Looking Statements\nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995. Statements in this press\nrelease that are not statements of historical fact are forward-looking\nstatements. Such forward-looking statements include, without limitation,\nstatements regarding: expectations of Artiva regarding the potential benefits,\naccessibility, effectiveness and safety of AlloNK; Artiva's Phase 3\nregistrational trial for AlloNK(®); and Artiva's participation in the 2026\nCantor Global Healthcare Conference and H.C. Wainwright 28th Annual Global\nInvestment Conference. These forward-looking statements are based on the\nbeliefs of the management of Artiva as well as assumptions made by and\ninformation currently available to Artiva. Such statements reflect the current\nviews of Artiva with respect to future events and are subject to known and\nunknown risks and uncertainties, including, without limitation, risks inherent\nin developing product candidates and risks related to the legal and regulatory\nframework for the industry. In light of these risks and uncertainties, the\nevents or circumstances referred to in the forward-looking statements may not\noccur. These and other factors that may cause Artiva's actual results to\ndiffer from current expectations are discussed in Artiva's filings with the\nSecurities and Exchange Commission (the “SEC”), including the section\ntitled “Risk Factors” in Artiva's Quarterly Report on Form 10-Q for the\nquarter ended June 30, 2026. You are cautioned not to place undue reliance on\nthese forward-looking statements, which speak only as of the date this press\nrelease is given. Except as required by law, Artiva undertakes no obligation\nto publicly update any forward-looking statements, whether as a result of new\ninformation, future events or otherwise.\n\nContacts\n\nInvestors & Media\nNoopur Batsha Liffick, MPH\nNBL LifeSci Advisory LLC\nir@artivabio.com\n\nSource: Artiva Biotherapeutics, Inc.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/0392544b-ecff-4590-9eed-59c934e1ba4d)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-02T12:30:00.780383217Z","server_sent_at_ms":1788352200780},"received_at":"2026-09-02T12:30:00.865Z","source_url":"https://www.globenewswire.com/news-release/2026/09/02/3355154/0/en/artiva-biotherapeutics-to-participate-in-upcoming-investor-conferences-in-september.html"},"analysis":{"id":"122792","press_release_id":"133899","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Artiva Biotherapeutics management will present live fireside chats at two September investor conferences: the 2026 Cantor Global Healthcare Conference on September 9 at 10:20 am EDT and the H.C. Wainwright 28th Annual Global Investment Conference on September 14 at 2:30 pm EDT.\n\nManagement will also be available for 1x1 meetings with registered investors, and webcast replays will remain on Artiva's website for 90 days.\n\nThe release contains no new clinical or financial data; it reiterates prior plans to initiate a Phase 3 registrational trial of lead program AlloNK (AB-101) in refractory rheumatoid arthritis in the second half of 2026.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine IR scheduling notice; at most a calendar hook for the September 9 and September 14 fireside chats."},"keyFigures":{},"namedEntities":{"people":[{"name":"Noopur Batsha Liffick, MPH","role":"investor and media relations contact (NBL LifeSci Advisory LLC)"}],"products":["AlloNK (AB-101)","anti-CD20 antibodies"],"companies":[{"name":"Artiva Biotherapeutics, Inc.","ticker":"ARTV","relationship":"filer"},{"name":"Cantor Fitzgerald","relationship":"conference host (2026 Cantor Global Healthcare Conference)"},{"name":"H.C. Wainwright","relationship":"conference host (28th Annual Global Investment Conference)"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine investor-conference scheduling notice with fireside chat logistics; contains no new clinical, financial, or regulatory information. Pure IR boilerplate."},"tickerRelevance":{"others":[],"primary":"ARTV"},"globalImportance":6,"audienceRelevance":12,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap clinical-stage biotech","eventGravity":"routine-ir-conference-notice","newInformation":false,"householdBrandBoost":0,"retailFavoriteBoost":0}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Artiva Biotherapeutics management will present live fireside chats at two September investor conferences: the 2026 Cantor Global Healthcare Conference on September 9 at 10:20 am EDT and the H.C. Wainwright 28th Annual Global Investment Conference on September 14 at 2:30 pm EDT.\n\nManagement will also be available for 1x1 meetings with registered investors, and webcast replays will remain on Artiva's website for 90 days.\n\nThe release contains no new clinical or financial data; it reiterates prior plans to initiate a Phase 3 registrational trial of lead program AlloNK (AB-101) in refractory rheumatoid arthritis in the second half of 2026.","key_figures":{},"named_entities":{"people":[{"name":"Noopur Batsha Liffick, MPH","role":"investor and media relations contact (NBL LifeSci Advisory LLC)"}],"products":["AlloNK (AB-101)","anti-CD20 antibodies"],"companies":[{"name":"Artiva Biotherapeutics, Inc.","ticker":"ARTV","relationship":"filer"},{"name":"Cantor Fitzgerald","relationship":"conference host (2026 Cantor Global Healthcare Conference)"},{"name":"H.C. Wainwright","relationship":"conference host (28th Annual Global Investment Conference)"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-02T15:03:02.562Z","global_importance":6,"audience_relevance":12,"importance_components":{"tickerTier":"small-cap clinical-stage biotech","eventGravity":"routine-ir-conference-notice","newInformation":false,"householdBrandBoost":0,"retailFavoriteBoost":0}},"durationMs":324810,"modelName":"glm-4.7"}}